BTIG Reiterates Buy Rating on Seelos Therapeutics (SEEL) on 'Robust' Data
Tweet Send to a Friend
BTIG analyst Bob Hazlett reiterated a Buy rating and $14.00 price target on Seelos Therapeutics (NASDAQ: SEEL) after the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
